Antibodies and molecules derived therefrom that bind to STEAP-1 proteins

• US 7,494,646 B2
• Filed: 04/23/2004
• Issued: 02/24/2009
• Est. Priority Date: 09/06/2001
• Status: Expired due to Term

• Current Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Original Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Inventors: Gudas, Jean, Raitano, Arthur B., Jia, Xiao-Chi, Faris, Mary, Challita-Eid, Pia M., Perez-Villar, Juan J., Jakobovits, Aya, Morrison, Karen J., Etessami, Soudabeh
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Halvorson; Mark
• Application Number:
  US10/830,899
• Publication Number:
  US 20040253232A1
• Time in Patent Office: 1,768 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A01K 67/0271 Chimeric vertebrates, e.g. comprising exogenous cells
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 51/1045 against animal or human tumor cells or tumor cell determinants
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 14/723 G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/77 Internalization into the cell
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 9/0091 oxidizing metal ions (1.16)
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

Claims

1. A method of delivering a cytotoxic agent or a diagnostic agent to a cell that expresses a STEAP-1 protein (SEQ ID NO:

2), comprising providing a cytotoxic agent, a therapeutic agent or a diagnostic agent conjugated to;

(a) an antibody or antibody fragment, comprising all heavy and light chain complementarity determining regions (CDRs) from an antibody designated X92.1.30.1.1(1) (ATCC Accession number PTA-5802) or X120.545.1.1 (ATCC Accession number PTA-5803), or

(b) an antibody or antibody fragment, comprising the heavy chain variable region sequence of SEQ ID NO;

50 and a light chain variable region sequence selected from the group consisting of SEQ ID NO;

52, SEQ ID NO;

54 and SEQ ID NO;

56,

wherein the antibody or antibody fragment of (a) and (b) binds to the STEAP-1 protein (SEQ ID NO;

     2),

to form an antibody-agent or antibody fragment-agent conjugate; and

exposing the cell to the antibody-agent or antibody fragment-agent conjugate.

2. The method of claim 1, wherein the cytotoxic agent or the diagnostic agent comprises a detectable marker or a toxin.

3. The method of claim 2, wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a substrate, a cofactor, an inhibitor, a fluorescent compound, a bioluminescent compound, a magnetic particle or a chemiluminescent compound.

4. The method of claim 3, wherein the radioisotope comprises ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, ¹⁸⁶RE, ²¹¹At, ¹²⁵I, ¹⁸⁸Re, ¹⁵³Sm, ²¹³Bi, ³²P, or Lu.

5. The method of claim 2, wherein the toxin comprises ricin, ricin A-chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinbiastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatin, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, cc1065, or a cisplatin.

6. The method of claim 5 wherein the toxin comprises auristatin.

7. The method of claim 1, wherein the antibody is a monoclonal antibody.

8. The method of claim 1, wherein the antibody is designated X92.1.30.1.1(1) and assigned A.T.C.C. Accession No.:

PTA-5802.

9. The method of claim 1, wherein the antibody is designated X120.545.1.1 and assigned A.T.C.C. Accession No.:

PTA-5803.

10. The method of claim 7, wherein the monoclonal antibody is a humanized antibody.

11. The method of claim 1, wherein the antibody fragment is an Fab, F(ab′

)₂, Fv or Sfv fragment.

12. The method of claim 1, wherein the antibody or antibody fragment are chimeric.

13. The method of claim 1, wherein the antibody or antibody fragment thereof is recombinantly produced.

14. The method of claim 13, wherein the recombinant protein comprises the antigen binding region.

15. The method of claim 1, wherein the therapeutic agent comprises paclitaxel, an androgen blocker, or an immune modulator.

16. The method of claim 1, further comprising the administration of radiation, chemotherapy, or hormone ablation.

17. The method of claim 1 wherein the antibody or antibody fragment is administered to a human patient who has received one or more rounds of chemotherapy prior to the administration of said antibody or antibody fragment.

18. The method of claim 1 wherein the antibody comprises the six complementary determining regions (CDRs) from an antibody designated X92. 1.30.1.1(1) (ATCC Accession number PTA-5802) or X120.545.1.1 (ATCC Accession number PTA-5803).

19. The method of claim 1 wherein the antibody comprises the amino acid sequence of SEQ ID NO:

52.

20. The method of claim 1 wherein the antibody comprises the amino acid sequence of SEQ ID NO:

54.

21. The method of claim 1 wherein the antibody comprises the amino acid sequence of SEQ ID NO:

56.